A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation

• Published in: Vaccine Vol. 34; no. 31; pp. 3607 - 3612
• Main Authors: Hannaman, Drew, Dupuy, Lesley C., Ellefsen, Barry, Schmaljohn, Connie S.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 30.06.2016; Elsevier Limited
• Subjects: Adolescent; Adult; Allergy and Immunology; Alphavirus; antibodies; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Clinical trial; clinical trials; Deoxyribonucleic acid; DNA; DNA vaccine; Double-Blind Method; Electroporation; Encephalitis; Encephalitis Virus, Venezuelan Equine; Encephalomyelitis, Venezuelan Equine - prevention & control; Female; genes; Hispanic Americans; horses; Human; Humans; immune response; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulins; Injection; Injections, Intradermal; Injections, Intramuscular; Intradermal; Intramuscular; Male; Middle Aged; Phase 1; questionnaires; R&D; recombinant vaccines; Reoviridae; Research & development; Studies; Togaviridae; Vaccines; Vaccines, DNA - administration & dosage; Vaccines, DNA - therapeutic use; Venezuelan equine encephalitis; Venezuelan equine encephalitis virus; Viral Vaccines - administration & dosage; Viral Vaccines - therapeutic use; Young Adult; DNA vaccine; Human; Intradermal; Venezuelan equine encephalitis; Electroporation; Clinical trial; Intramuscular; Phase 1

Venezuelan equine encephalitis virus (VEEV), a mosquito-borne alphavirus, causes periodic epizootics in equines and is a recognized biological defense threat for humans. There are currently no FDA-licensed vaccines against VEEV. We developed a candidate DNA vaccine expressing the E3-E2-6K-E1 genes o...